Targeting key regulators of the cancer stem cell phenotype to overcome their critical influence on tumor growth is a promising new strategy for cancer treatment. Here we present a modeling framework that operates at both the cellular and molecular levels, for investigating IL-6 mediated, cancer stem cell driven tumor growth and targeted treatment with anti-IL6 antibodies. Our immediate goal is to quantify the influence of IL-6 on cancer stem cell self-renewal and survival, and to characterize the subsequent impact on tumor growth dynamics. By including the molecular details of IL-6 binding, we are able to quantify the temporal changes in fractional occupancies of bound receptors and their influence on tumor volume. There is a strong correlation between the model output and experimental data for primary tumor xenografts. We also used the model to predict tumor response to administration of the humanized IL-6R monoclonal antibody, tocilizumab (TCZ), and we found that as little as 1mg/kg of TCZ administered weekly for 7 weeks is sufficient to result in tumor reduction and a sustained deceleration of tumor growth.
A mathematical model for IL-6-mediated, stem cell driven tumor growth and targeted treatment
F. Nazari,A. Pearson,J. Nör,Trachette L. Jackson
Published 2018 in PLoS Comput. Biol.
ABSTRACT
PUBLICATION RECORD
- Publication year
2018
- Venue
PLoS Comput. Biol.
- Publication date
2018-01-01
- Fields of study
Biology, Mathematics, Medicine, Computer Science
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-79 of 79 references · Page 1 of 1
CITED BY
Showing 1-36 of 36 citing papers · Page 1 of 1